Amino Acid, Peptide, or Protein

Pfizer Closes Metsera Deal, Officially Ending Bidding War Drama

2 days ago talkbio0Tagged Acquisition, bidding war, CVR, Glucagon-Like Peptide 1, Metsera, Nordisk, Obesity, Pfizer, regulatory certainty

Pfizer; Metsera; acquisition; Novo Nordisk; bidding war; obesity drugs; GLP-1; CVR; regulatory certainty

MacroGenics Stops Bispecific Development; Third Arc Bio Signs $840M Licensing Deal with Adagene

2 days ago talkbio0Tagged Adagene, Antibodies, Bispecific, Arc Bio, CD3 T cell, Clinical Trials, engagers, licensing agreement, lorigerlimab, MacroGenics, mCRPC, SAFEbody technology

MacroGenics; lorigerlimab; bispecific antibody; mCRPC; clinical trial halt; Third Arc Bio; Adagene; SAFEbody technology; CD3 T cell engagers; licensing agreement; biotech deals

Merck Q3 2025: Solid Organic Growth Across All Sectors

4 days ago talkbio0Tagged Acquisition, Animal Health, Gross margin, Keytruda, Merck, Neoplasms, new product, organic growth, Pharma, Q3 2025, Verona

Merck; Q3 2025; Organic growth; KEYTRUDA; Oncology; Animal Health; Verona Pharma acquisition; Gross margin; Revenue; New product launches

From Weight Loss to Hair Loss: The Search for the Next Blockbuster – Recent Developments and News (2024-2025)

5 days ago talkbio0Tagged Alopecia, Androgenetic Alopecia, baldness cure, blockbuster drugs, Glucagon-Like Peptide 1, Investments, minoxidil, pattern hair loss, Pelage Pharmaceuticals, PP405, Veradermics, Weight-Loss Agents

weight loss drugs; GLP-1; hair loss treatments; Pelage Pharmaceuticals; Veradermics; blockbuster drugs; pattern hair loss; baldness cure; minoxidil; PP405; androgenetic alopecia; biotech investment

AnaptysBio Halts Phase 2 Ulcerative Colitis Trial; Lyell Immunopharma Secures CAR-T Rights

5 days ago talkbio0Tagged AnaptysBio, CAR-T therapy, Clinical Failure, Clinical Trials, Discontinuation (procedure), Lyell Immunopharma, News [Publication Type], Phase 2 trial, Rheumatoid Arthritis, Rosnilimab, Ulcerative Colitis

AnaptysBio; rosnilimab; ulcerative colitis; Phase 2 trial; clinical failure; trial discontinuation; Lyell Immunopharma; CAR-T therapy; licensing deal; biotech news; rheumatoid arthritis

Nkarta Reports Third Quarter 2025 Financial Results and Corporate Highlights

5 days ago talkbio0Tagged Capitalization, clinical-stage biopharma, development aspects, exophthalmos producing substance, financial results, Impaired, Market, net loss, Nkarta, Operating expenses, Q3, research

Nkarta; Q3 2025 financial results; net loss; operating expenses; EPS; research and development; impairment; market capitalization; clinical-stage biopharma; corporate highlights

UbiVac Showcases First ‘Dark Matter’ Cancer Immunotherapy Clinical Data at SITC 2025 Annual Meeting

6 days ago talkbio0Tagged Allogeneic Autophagosome-enriched Vaccine DPV-001, alternatives, anti-PD-1, Clinical Trials, Combined Modality Therapy, Dark color, dark matter, Genome, immunopeptidome, Immunotherapy for cancer, Malignant Head and Neck Neoplasm, Neoantigen, SITC, T-Cell Receptor, UbiVac

UbiVac; DPV-001; cancer immunotherapy; dark matter; dark genome; alternatives neoantigens; T cell receptor (TCR); head and neck cancer; SITC 2025; clinical trial; combination therapy; anti-PD-1; immunopeptidome

Amgen’s Repatha Reduces First-Time Cardiovascular Events by 25% in Major Clinical Trial

6 days ago talkbio0Tagged amgen, Cardiovascular event, Cholesterol Drug, Clinical Trials, evolocumab, LDL Cholesterol Lipoproteins, Myocardial Infarction, PCSK9 inhibitor, Primary Prevention, Repatha, VESALIUS-CV

Amgen; Repatha; evolocumab; cholesterol drug; PCSK9 inhibitor; cardiovascular events; clinical trial; VESALIUS-CV; primary prevention; heart attack; LDL cholesterol

Pfizer Triumphs Over Novo Nordisk with $10B Bid to Acquire Metsera

6 days ago talkbio0Tagged Acquisition, Approved, bidding war, Drug Industry, Glucagon-Like Peptide 1, Metsera, Nordisk, Obesity, Pfizer, shareholder

Pfizer; Novo Nordisk; Metsera; obesity drugs; GLP-1; acquisition; bidding war; shareholder approval; pharmaceutical industry

FDA Extends Review Period for Rhythm Pharmaceuticals’ Imcivree (Setmelanotide) in Acquired Hypothalamic Obesity

1 week ago talkbio0Tagged Agonist, amendment, goal, Hypothalamic structure, Imcivree, MC4R protein, human, PDUFA, Phase 3 trial, review extension, Rhythm Pharmaceuticals, setmelanotide, United States Food and Drug Administration

Imcivree; Rhythm Pharmaceuticals; FDA; review extension; acquired hypothalamic obesity; setmelanotide; PDUFA goal date; Phase 3 trial; major amendment; MC4R agonist